UROGEN PHARMA LTD
Develops therapies to treat urological conditions
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Urogen Pharma's stock with a target price of $43.88, indicating strong growth potential.
Financial Health
Urogen Pharma is earning strong revenue and profits, with healthy cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring URGN
New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial momentum
JELMYTO and other commercial activities can drive revenue growth if adoption and reimbursement progress; revenue can be uneven and is subject to payer decisions.
Platform potential
The local delivery platform aims to improve drug retention in the urinary tract, which may offer clinical advantages; clinical validation and uptake remain key uncertainties.
Regulatory pathway
Approvals, label expansions and international reimbursement shape long-term prospects, though regulatory and market hurdles can create volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
